首页> 外文期刊>Acta Haematologica >Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as ipss intermediate-1
【24h】

Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as ipss intermediate-1

机译:血清铁蛋白是中国患有骨髓增生异常综合症的独立预后因素,分类为ipss medium-1

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The International Prognostic Staging System (IPSS) for myelodysplastic syndromes (MDS) was developed predominately in patients of European ancestry and is not validated in Asians. In a recently revised IPSS (IPSS-R), several new prognostic variables are included, i.e. age, Eastern Cooperative Oncology Group performance score (ECOG PS), serum ferritin and lactate dehydrogenase. Chinese with MDS offer a unique opportunity to distinguish the prognostic impacts of haemoglobin (HGB) concentration, red blood cell (RBC) transfusions and serum ferritin because in China, patients rarely receive RBC transfusions unless the HGB concentration is <6.0 g/dl. Methods: We studied prognostic variables in 191 untreated Chinese primary patients with MDS intermediate-1 (INT-1) in the IPSS. Results: Serum ferritin level ≥500 μg/l at diagnosis was a strong independent predictor of survival. Although baseline serum ferritin level was inversely correlated with baseline HGB, it was the serum ferritin, not the baseline HGB level, that was significantly correlated with survival in Chinese patients. A new prognostic scoring system including the ECOG PS, absolute neutrophil level, serum ferritin, percentage of bone marrow blasts and poor karyotype was developed for Chinese with IPSS INT-1 MDS. Conclusions: This revised scoring system identified a subgroup of Chinese with MDS and INT-1 IPPS who have a poor prognosis and may benefit from more intensive therapy.
机译:背景:骨髓增生异常综合征(MDS)的国际预后分期系统(IPSS)主要在欧洲血统的患者中开发,未经亚洲人验证。在最近修订的IPSS(IPSS-R)中,包括了几个新的预后变量,即年龄,东部合作肿瘤小组表现评分(ECOG PS),血清铁蛋白和乳酸脱氢酶。患有MDS的中国人提供了一个独特的机会来区分血红蛋白(HGB)浓度,红细胞(RBC)输血和血清铁蛋白的预后影响,因为在中国,除非HGB浓度<6.0 g / dl,否则患者很少接受RBC输血。方法:我们研究了191名未经治疗的中国原发性IPSS中MDS中间1(INT-1)患者的预后变量。结果:诊断时血清铁蛋白水平≥500μg/ l是生存的强烈独立预测因子。尽管基线血清铁蛋白水平与基线HGB呈负相关,但血清铁蛋白而不是基线HGB水平与中国患者的生存率显着相关。针对患有IPSS INT-1 MDS的中国人,开发了一种新的预后评分系统,包括ECOG PS,绝对中性粒细胞水平,血清铁蛋白,骨髓母细胞百分比和不良核型。结论:该修订的评分系统确定了患有MDS和INT-1 IPPS的中国人亚组,这些亚组的预后较差,可能会从更深入的治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号